CX 2020 LIVE: Overwhelming 91% of specialist audience favours venous stents
dawn2020-06-19T13:35:41+01:00
Roger Greenhalgh (top left), Armando Mansilha (top middle), Manj Gohel (top right), Christopher Cheng (bottom left), Michael Jolly (bottom middle), and Houman Jalaie (bottom right)
A poll of an enthused audience of venous specialists during the CX 2020 LIVE Deep Venous Disease Consensus […]
CX 2020 LIVE gains CME accreditation: Attendees from 79 countries participate live
dawn2020-06-03T18:13:26+01:00Covered endoprostheses gain key role in management of aortoiliac occlusive disease
dawn2020-06-02T08:57:44+01:00
Michele Antonello (top) chairs the discussion, following the Industry Symposium, with Amer Zanabili and Bella Huasen.
The first session of CX 2020 LIVE also featured an Industry Symposium titled “Endovascular treatment of complex aortoiliac occlusive disease” (sponsored by Gore). Chaired by Michele Antonello […]
Comprehensive innovation programme gives insights into the technologies of the future
dawn2019-09-26T15:00:31+01:00The CX Innovation Programme showcased technological developments happening in all areas of the Charing Cross Symposium: acute stroke, aortic, peripheral, venous, vascular access, and wound care. Additionally, a new “Dragons’ Den” winner was crowned.
In the first talk of the session, Lindsay Machan (Vancouver, Canada) talked about the lessons he had learnt from being a founder […]
VenaSeal maintains safety and efficacy at extended five-year follow-up
dawn2019-04-16T21:52:45+01:00
Nick Morrison
The first-ever 60-month data on Medtronic’s VenaSeal closure system were presented on Tuesday, indicating that at five years, treatment with the cyanoacrylate adhesive for closure of diseased vein segments was not inferior to the alternative treatment arm of radiofrequency ablation (RFA). Nick Morrison of […]
CX 2020 Abstracts
dawn2019-11-22T13:30:34+00:00
Abstract Submissions for CX 2020 are now closed
The CX Abstract Board is calling for senior and trainee doctors in the vascular and endovascular field to submit their abstracts for presentation at the Charing Cross Symposium (21–24 April 2020, London, UK).
The best abstract presentation […]
CX Abstract and Poster Prize winners announced!
dawn2019-09-30T11:51:58+01:00
Poster prize winner Wei-Wen Ang with CX Abstract Board and Poster member Anna Prent
At Charing Cross 2018, abstracts were presented—across 17 sessions—on the five programme areas of CX: Acute stroke, Thoracic Aortic Abdominal Aortic, Peripheral, Venous, and Vascular Access. Additionally, throughout the symposium, delegates […]
One-year outcomes of EndoAnchor study adds ESAR—endosuture aneurysm repair—to the endovascular lexicon
dawn2018-04-27T10:01:22+01:00
Frank Arko
Frank Arko (Charlotte, USA) presented one-year results from the 70-patient short-neck cohort of the ANCHOR Registry. Patients were treated with an endograft and endoanchors (Endurant and Heli-FX, Medtronic) for abdominal aortic aneurysm. The data showed “very good clinical outcomes in a challenging patient population”, Arko […]
Low early mortality and high technical success for novel thoracic stent graft
dawn2018-04-27T10:33:59+01:00
A physician-sponsored investigational device exemption trial on thoracic endovascular aortic repair (TEVAR) using a new thoracic stent graft (Valiant thoracoabdominal aortic aneurysm stent graft, Medtronic), along with its initial 30-day data, was revealed at a Podium 1st presentation at CX 2018 by Thomas Maldonado (New York, USA). […]
First case experience presented with next generation conformable EVAR device
dawn2018-04-27T09:29:05+01:00
CX delegates were presented data from the first 10 EVAR patients treated using a new conformable device, the Gore Excluder conformable abdominal aortic aneurysm endoprosthesis with active control system, yesterday.
Robert Rhee (Brooklyn, New York), the national principal investigator of the US investigational device exemption (IDE) trial for […]
“Fantastic” live case demonstrates potential value of intravascular lithotripsy
dawn2018-04-27T09:56:24+01:00
In an exciting session yesterday, the CX audience witnessed the demonstration of a novel treatment strategy with intravascular lithotripsy for calcified arterial stenosis. It will now become a CX tradition to feature live cases to showcase what has been discussed in the presentations, so that the audience […]
Live cases to illustrate the data: The future of the Charing Cross Symposium
dawn2018-04-27T09:06:25+01:00
In yesterday’s plenary programmes, the future of the Charing Symposium was launched with the initiation of live case demonstrations to illustrate key data discussed on the programme. This year, both the Thoracic Aortic programme and the Peripheral Critical Ischaemia programme featured these illuminating cases, which stirred discussion and […]
STEP seeks to advance patient safety after TEVAR
dawn2018-04-27T10:06:45+01:00
Stroke is a major concern following TEVAR (thoracic endovascular aortic repair) and Charing Cross delegates heard the results from a collaborative study that pooled practice data from a number of high-volume centres in order to benefit patients undergoing the procedure. A highlight of the session was the […]
CX 2018: Landmark EVRA trial provides first Level 1 evidence for early endovenous ablation
dawn2018-04-25T10:25:09+01:00
The first full results of the Early Venous Reflux Ablation (EVRA) ulcer study were presented at the Charing Cross Symposium yesterday. The presentation was accompanied by simultaneous publication in the New England Journal of Medicine after the session.
The randomised trial revealed that early endovenous ablation outperforms deferred […]
Majority of CX audience decides endovascular-first strategy for critical limb ischaemia is a concept without evidence
dawn2018-04-25T10:26:13+01:00
At the CX Great Debate held yesterday, vascular and endovascular surgery titans went head-to-head to debate the contentious topic “Endovascular-first strategy for critical limb ischaemia is a concept without evidence”. Arguing in favour of this motion were current Society for Vascular Surgery (SVS) president Clement […]
Drug-coated balloon is “highly effective and safe” and shows outstanding clinical improvement for patients compared to an uncoated balloon
dawn2018-04-25T10:49:59+01:00
Ulf Teichgraeber
The 12-month results from the full clinical cohort of the EffPAC randomised controlled trial, were presented for the first time at the CX Symposium yesterday.
Target lesion revascularisation at 12 months was 1.3% (vs 17.7% in the plain angioplasty group, p<0.001). Primary patency at 12 months […]
Paclitaxel-eluting stent fails BATTLE against bare metal stent
dawn2018-04-25T10:29:09+01:00
Yann Gouëffic
The BATTLE trial comparing a drug-eluting stent (Zilver PTX, Cook) vs. a bare metal stent (Misago, Terumo) for the treatment of intermediate femoropopliteal lesions has failed to the show superiority of the paclitaxel-coated stent at one-year follow-up. The trial highlights a need for further direct […]
CX 2018: Record number of hands-on workshop opportunities for those technical tips and tricks!
dawn2019-09-09T09:24:57+01:00This year, there are four CX Workshops that offer a record number of hands-on workshop opportunities for those technical tips and tricks. The CX Venous Workshop—which has now been running for 10 years—has more than 80 workstations over two days. Last year, a staggering 1,100 people attended this workshop. Located in the Venous City, […]
CX@CEC: Focus on challenging aortic disease
dawn2019-09-09T09:26:03+01:00
Rodney White
This year’s annual China Endovascular Course (CEC; 2–5 November, Beijing, China) played host to the first CX@CEC session, in collaboration with the Charing Cross Symposium. Focused on complex aortic disease, this session featured a selection of international and Chinese experts […]
CX 2018: Acute Stroke to explore the greatest carotid controversies of the day
dawn2018-03-27T17:26:38+01:00
Ross Naylor at CX 2017
CX 2018 will close with the Acute Stroke CONTROVERSIES programme, which Ross Naylor—a member of the CX Programme Organising Board—promises will be a memorable session. The highlight will be five debates that will address a few “sacred cows” that arouse considerable controversy around […]
CX 2018: 40 Years of Looking Forward with vascular education as it should be!
dawn2019-09-09T09:27:16+01:00This year, CX celebrates 40 Years of Looking Forward. In this video, members of the CX Programme Organising Board and the CX Faculty explain why CX is not only unique but also provides vascular education “as it should be”! Register now for CX 2018!
[…]
CX 2018: “I believe delegates of CX 2018 should attend this presentation since the information provided by it will change their practice”
dawn2019-09-09T09:29:42+01:00
Juan Parodi (San Isidro, Argentina) gives an opening talk at CX 2018 “Reversal of lower extremity intermittent claudication and rest pain by hydration”. Come to CX on Day 1 to see if it as simple as that! Read the interview below for more information.
What are the limitations […]
The opportunity for discussion is a key benefit of CX
dawn2018-02-15T14:35:40+00:00Fabrizio Fanelli (Florence, Italy), CX Faculty, says that a key point about CX is that it – unlike other meetings – provides opportunities for discussion. He notes that the “active discussion” at the podium is “very important” for what you learn at the meeting. Register for CX 2018!
[…]
CX has had “a very significant impact on my practice”
dawn2018-04-05T17:53:26+01:00CX Faculty member Barry Katzen (Miami, United States) discusses how attending CX has affected his clinical practice and how he always is “universally losing” debates at CX! Register for CX 2018!
“Excellent” is the word Prof Davies uses to describe CX
dawn2018-02-15T14:27:22+00:00CX programme organising board member Alun Davies (Imperial College, London, United Kingdom) reviews how CX has changed in the last 24 years that he has been attending the symposium, his most memorable moments, and the one word he would use to describe the meeting. Register for CX 2018!
[…]
“Every time I come to CX, I learn more and more”
dawn2018-02-15T14:20:26+00:00“One of the great things” about CX, according to CX Faculty member Kathleen Gibson (Bellevue, United States), is that it provides a “global perspective”. She says she “learns more and more” every time she attends. Register for CX 2018!
CX is “a very good forum” for new technologies
dawn2018-02-15T13:13:21+00:00Rodney White (Torrance, United States), CX Faculty, says that CX has been a “very good forum” for not only new technologies but also how we adapt them to current practice. He notes that CX chairman Roger Greenhalgh has always been at the forefront of the latest developments. Register for CX 2018!